"The voice for cancer physicians and their patients in Massachusetts."

FDA approves ibrutinib (IMBRUVICA) plus rituximab for chronic lymphocytic leukemia

23 Apr 2020 10:50 AM | Anonymous

The U.S. Food and Drug Administration expanded the indication of ibrutinib (IMBRUVICA, Pharmacyclics LLC) to include its combination with rituximab for the initial treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Read full press release

© Copyright.  All rights reserved. 

Massachusetts Society of Clinical Oncologists

P.O. Box 549154, Waltham, MA, 02454
Tel: 781.434.7329 | Fax: 781.464.4896 | email: msco@mms.org

Powered by Wild Apricot Membership Software